NCT00109187View on ClinicalTrials.gov

An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g

PHASE3CompletedINTERVENTIONAL
0
Timeline

Start Date

June 30, 2002

Study Completion Date

April 30, 2003

Conditions
Asthma
Interventions
DRUG

Xolair (omalizumab)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY